Racial differences in treatment and survival from early-stage breast carcinoma. Cancer 95, 1759-1766

Division of Health Promotion and Education, University of Northern Iowa, Cedar Falls, Iowa 50614-0241, USA.
Cancer (Impact Factor: 4.89). 10/2002; 95(8):1759-66. DOI: 10.1002/cncr.10827
Source: PubMed

ABSTRACT African-American women have a significantly worse prognosis from breast carcinoma compared with white women, even when the stage at diagnosis is equivalent. The purpose of this study was to analyze racial differences in the treatment (use of breast-conserving surgery and radiation therapy) of women with early-stage breast carcinoma and the resulting effects on survival rates.
Subjects included 10,073 African-American and 123,127 white women diagnosed with Stage I, IIA, or IIB breast carcinoma in the National Cancer Institute's Surveillance, Epidemiology, and End Results program between 1988 and 1998. Comparisons were made by race with treatment, age, hormone receptor status, and stage at the time of diagnosis. Survival analyses were conducted to compare risk of death for African-American and white women while controlling for age, stage, and hormone receptor status.
Among women diagnosed with early-stage breast carcinoma who receive breast-conserving surgery, African-American women were significantly less likely to receive follow-up radiation therapy in every 10-year age group except in the older than 85 age group. Whether treatment was equivalent or suboptimal, survival for African-American women with early-stage breast carcinoma was significantly worse. However, when treatment was equivalent, the effects of racial differences on survival were significantly less compared with survival associated with suboptimal treatment.
Significant racial differences exist in the treatment of women with early-stage breast carcinoma. Public health efforts to eliminate suboptimal treatment would reduce, but not eliminate, racial disparity in survival.

1 Read
  • Source
    • "worldwide and 30.9/100.000 in developed countries [14]. One-third of these cancer deaths can be avoided by early detection and appropriate therapy; this means that nearly 400.000 lives could be saved every year [15]. Current investigation of breast cancer is performed in women between 50 and 70 years of age by X-ray mammography, sometimes supplemented by ultrasound and/or magnetic resonance imaging (MRI) [16]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose. To determine the diagnostic accuracy of DOBIComfortScan in patients with Breast Imaging Reporting suspect breast lesions (BI-RADS) 4-5 breast lesions. Materials and Methods. One-hundred and thirteen patients underwent DOBIComfortScan examination before surgery. Twelve parameters were taken into consideration to define DOBI findings. Results. Twenty-seven radical mastectomies, 47 quadrantectomies and 39 wide excisions, were performed. Overall, 65 invasive cancer, 9 in situ carcinoma and 39 nonmalignant lesions, were observed. Ten out of 12 considered parameters resulted significantly in association with histology at discriminant analysis. A summation score of 30.5 resulted to be the best cut off at ROC analysis, giving a sensitivity and specificity of 80% and 87%, respectively, and a positive predictive value of 92.2%. Finally the following DOBI-BI-RADS model was developed: malignant B5 ≥ 38 score); possibly malignant (B4 = 25 − 37 score); benign but the possibility of malignancy cannot be excluded (B3 = 20 − 24 score); benign (B2 < 20 score). Conclusion. definition of other parameters permits to improve the accuracy of this procedure. Further studies are warranted to define the potential role of DOBIComfortScan in breast cancer imaging.
    09/2012; 2012:631917. DOI:10.5402/2012/631917
  • Source
    • "Moreover, Singh et al. [42] and Launay et al. [43] found that at every stage of diagnosis, breast cancer patients from lower-income areas had lower 5-year relative survival rates did than did those from higher-income areas. The presence of additional illnesses and treatment disparities may contribute to these differences [44,45]. Compared with less developed areas, more developed areas possess better detection techniques, and their cases have the ability to pay more for more accurate tests and more effective therapy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although socioeconomic status (SES) has been focused on as a key determinant of cancer stage at diagosis in western countries, there has been no systemic study on the relationship of SES and breast cancer stage at diagnosis in China. The medical charts of 4,211 eligible breast cancer patients from 7 areas across China who were diagnosed between 1999 and 2008 were reviewed. Four area-based socioeconomic indicators were used to calculate area-based SES by cluster analysis. The associations between area-based SES and stage at diagnosis were analyzed by trend chi-square tests. Binary logistic regression was performed to estimate odds ratios for individual demographic characteristics' effects on cancer stages, stratified by area-based SES. The individual demographic and pathologic characteristics of breast cancer cases were significantly different among the seven areas studied. More breast cancer cases in low SES areas (25.5%) were diagnosed later (stages III & IV) than those in high (20.4%) or highest (14.8%) SES areas (χ² for trend = 80.79, P < 0.001). When area-based SES is controlled for, in high SES areas, cases with less education were more likely to be diagnosed at later stages compared with more educated cases. In low SES areas, working women appeared to be diagnosed at earlier breast cancer stages than were homemakers (OR: 0.18-0.26). In China, women in low SES areas are more likely to be diagnosed at later breast cancer stages than those in high SES areas.
    BMC Cancer 03/2012; 12(1):122. DOI:10.1186/1471-2407-12-122 · 3.36 Impact Factor
  • Source
    • "These differences are causing a long term divergence in mortality trends between African American and white women. Many studies are showing that the disparity in breast cancer death rates between whites and blacks continues to grow with mortality rates higher among black women compared to white women (see, e.g., Joslyn, 2002; Marbella and Layde, 2001; Tarone, Chu, and Gaudette, 1997). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The disparity in breast cancer mortality rates among white and black US women is widening, with higher mortality rates among black women. We apply functional time series models on age-specific breast cancer mortality rates for each group of women, and forecast their mortality curves using exponential smoothing state-space models with damping. The data were obtained from the Surveillance, Epidemiology and End Results (SEER) program of the US [1]. Mortality data were obtained from the National Centre for Health Statistics (NCHS) available on the SEER*Stat database. We use annual unadjusted breast cancer mortality rates from 1969 to 2004 in 5-year age groups (45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84). Age-specific mortality curves were obtained using nonparametric smoothing methods. The curves are then decomposed using functional principal components and we fit functional time series models with four basis functions for each population separately. The curves from each population are forecast and prediction intervals are calculated. Twenty-year forecasts indicate an overall decline in future breast cancer mortality rates for both groups of women. This decline appears to be steeper among white women aged 55-73 and black women aged 60-84. For black women under 55 years of age, the forecast rates are relatively stable indicating there is no significant change in future breast cancer mortality rates among young black women in the next 20 years. White women have smooth and consistent patterns in breast cancer mortality rates for all age-groups whereas the mortality rates for black women are much more variable. The projections suggest, for some age groups, black American women may not benefit equally from the overall decline in breast cancer mortality in the United States.
    Cancer Epidemiology 10/2010; 34(5):542-9. DOI:10.1016/j.canep.2010.05.001 · 2.71 Impact Factor
Show more

Similar Publications


1 Read